DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Decoy Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.17+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $622.40K
- P/E (TTM)
- –
- Dividend yield
- –
Decoy Therapeutics Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Drug Development | – | – | – | $0 | $0 | $0 | $0 | – | – |
| Consumer Operations | – | – | – | $838.14K | $1.27M | $1.01M | $0 | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2018 | FY2017 | FY2016 | FY2015 | YoY |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | -$12.61M | -$5.73M | -$12.89M | – | – | – | – | +120.0% |
| Drug Development | – | – | – | -$11.89M | -$16.72M | -$19.62M | -$12.22M | – |
| Consumer Operations | – | – | – | -$1.98M | -$8.88M | -$10.02M | -$7.89M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | – | – | – | $826.52K | $1.26M | $989.92K | – | – | – |
| Other revenue | – | – | – | $11.63K | $13.53K | $20.75K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Decoy Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.